- UroToday Home
- Urologic Oncology
The Latest Research on CRPC with Bone Metastases
Recent Abstracts
-
Exercise for Individuals with Bone Metastases: A Systematic ReviewCRPC w/ bone metastasesJanuary 10, 2022
-
Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands.CRPC w/ bone metastasesDecember 3, 2021
-
Initiation of bone-targeted agents in patients with bone metastases and breast or castrate-resistant prostate cancer actively treated in routine clinical practice in Europe.CRPC w/ bone metastasesNovember 16, 2021
-
Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer.CRPC w/ bone metastasesSeptember 29, 2021
-
Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study.CRPC w/ bone metastasesSeptember 15, 2021
-
Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.CRPC w/ bone metastasesAugust 6, 2021
-
Prostate Cancer with Bone Metastases: Addressing Chronic Pain from the Perspective of the Radiation Oncology Nurse Practitioner.CRPC w/ bone metastasesJuly 29, 2021
-
Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy.CRPC w/ bone metastasesJuly 26, 2021
-
Assessment of the viability and treatment response of bone metastases in patients with metastatic castration-resistant prostate cancer using choline PET/CT.CRPC w/ bone metastasesJune 14, 2021
-
Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.CRPC w/ bone metastasesJune 8, 2021
Beyond the Abstracts
-
Bone Targeted Therapy and Skeletal Related Events in the Era of Enzalutamide and Abiraterone Acetate for Castration Resistant Prostate Cancer with Bone Metastases - Beyond the AbstractCRPC w/ bone metastasesOctober 27, 2020
-
Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT: Beyond the AbstractCRPC w/ bone metastasesApril 7, 2017
-
Prostate Cancer Cure is Possible: Beyond the AbstractCRPC w/ bone metastasesJanuary 5, 2017
-
The use of radium 223 dichloride in a multidisciplinary approach for treating metastatic castration-resistant prostate cancer, "Beyond the Abstract," by Elisa BorsòCRPC w/ bone metastasesFebruary 11, 2015
